Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Amy Sion"'
2
Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials
Autor: Jennifer Mikoll, Amy Sion, Erin R. Weeda, Jessica H McElwee, Theodore Stewart Gourdin
Publikováno v: Journal of Oncology Pharmacy Practice. 26:861-865
IntroductionDespite first-line approval in metastatic renal cell carcinoma (mRCC), the tyrosine kinase inhibitor cabozantinib is associated with frequent treatment-limiting side effects. Dose reductions in published trials of the drug and in clinical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099f3eb5a7f074677f2ac1342da419f5
https://doi.org/10.1177/1078155219875509
Zobrazit plný text záznamu
3
Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
Autor: Hammad Shafqat, Amy Sion, Theodore Stewart Gourdin
Publikováno v: Seminars in Oncology. 45:156-163
Immune-related adverse events (irAEs) are commonly encountered, when using programmed death-1/programmed death-ligand-1 (anti-PD-1/PD-L1) therapy and are often managed with corticosteroids. The effect of irAEs, particularly when steroids are required
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::204b3a5cbca56fd55ebedca07c925d82
https://doi.org/10.1053/j.seminoncol.2018.07.003
Zobrazit plný text záznamu
5
A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics
Autor: Kasey Jackson, Amy Sion, Rebekah Hartwell, Andrew Bodiford, Lynn A. Uber, Anastasia Graham, Carolyn Bondarenka, Cathy Letton, Andy Maldonado
Publikováno v: Journal of Oncology Pharmacy Practice. 25:847-854
Background Collaborative drug therapy management is a formal partnership between a pharmacist and physician to allow the pharmacist to manage a patient’s drug therapy. Literature supports collaborative disease therapy management can improve patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62cd48bc5ae3f09629513dca2fb21ff4
https://doi.org/10.1177/1078155218765629
Zobrazit plný text záznamu
6
Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors
Autor: Amy Sion, Jenessa Lee, Anastasia Graham
Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(8)
Immune checkpoint inhibitors are being commonly used as anticancer therapies to treat malignancies. Immune checkpoint inhibitors have been associated with numerous immune-related adverse events (irAEs). IrAEs are well documented; however, rheumatic i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f8012b6c4fd35ad6c287431fb3b3a6
https://pubmed.ncbi.nlm.nih.gov/30651028
Zobrazit plný text záznamu
7
Preliminary results from a phase II trial of docetaxel before castration with degarelix in men with newly diagnosed metastatic prostate cancer
Autor: Amy Sion, Thomas E. Keane, Jennifer Mikoll, Hong Li, Harry S. Clarke, Theodore Stewart Gourdin, Michael B. Lilly, Toros Dincman, Robert L. Grubb, David T. Marshall, Arif Hussain, David Sellman, Stephen J. Savage, Pooja Patel
Publikováno v: Journal of Clinical Oncology. 39:116-116
116 Background: Randomized trials have demonstrated a survival advantage to administering docetaxel (D) shortly after initiation of androgen deprivation therapy (ADT) in men with newly diagnosed hormone sensitive metastatic prostate cancer (hsMPC). C
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::763519e3be07336272395ab15ed6bd3e
https://doi.org/10.1200/jco.2021.39.6_suppl.116
Zobrazit plný text záznamu
8
Association of immune related adverse events with improved progression-free survival in patients receiving anti-PD-1 / PD-L1 therapy irrespective of corticosteroid use
Autor: Hammad Shafqat, Theodore Stewart Gourdin, Amy Sion
Publikováno v: Journal of Clinical Oncology. 36:e15088-e15088
e15088Background: Immune-related adverse events (irAEs) are commonly encountered when using anti-PD-1/PD-L1 therapy and are often managed with corticosteroids. The effect of irAEs, particularly whe...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2837ed979de6debc3fa7a52dec102e02
https://doi.org/10.1200/jco.2018.36.15_suppl.e15088
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje